TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF THE NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET 40
1.4 CURRENCY AND PRICING 42
1.5 LIMITATIONS 42
1.6 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.6 MULTIVARIATE MODELLING 52
2.7 PRODUCT AND SERVICE SEGMENT LIFELINE CURVE 52
2.8 MARKET END USER COVERAGE GRID 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 55
2.11 SECONDARY SOURCES 56
2.12 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
4.1 PESTEL ANALYSIS 61
4.2 PORTERS ANALYSIS 62
5 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, INDUSTRY INSIGHTS 63
6 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, REGULATIONS 65
7 MARKET OVERVIEW 68
7.1 DRIVERS 70
7.1.1 INCREASING DEMAND FOR TOXICOLOGY TESTING PRODUCTS 70
7.1.2 RAPIDLY GROWING PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES 70
7.1.3 RISING INVESTMENT IN R&D BY KEY MARKET PLAYERS 71
7.1.4 TECHNOLOGICAL ADVANCEMENTS TO DEVELOP NEW TOXICOLOGY TESTING METHODS 71
7.2 RESTRAINTS 72
7.2.1 HIGH COSTS ASSOCIATED WITH IN-VITRO TOXICOLOGY TESTING AND PRODUCTS 72
7.2.2 COMPLEXITY OF BIOLOGICAL SYSTEMS 72
7.2.3 NEED FOR SKILLED PERSONNEL AND INFRASTRUCTURE 73
7.3 OPPORTUNITIES 73
7.3.1 GROWING ADOPTION OF QUALITY CHECK PRODUCTS TO PREVENT PRODUCT RECALLS 73
7.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS FOR MARKET EXPANSION 74
7.3.3 GROWING DEMAND FOR PERSONALIZED MEDICINE AND PRECISION TOXICOLOGY 74
7.4 CHALLENGES 75
7.4.1 ETHICAL AND PUBLIC PERCEPTION 75
7.4.2 REGULATORY ACCEPTANCE AND ENDORSEMENT OF IN-VITRO TESTING METHODS 75
8 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT AND SERVICE 76
8.1 OVERVIEW 77
8.2 CONSUMABLES 80
8.3 SERVICES 81
8.3.1 CYTOTOXICITY 82
8.3.2 GENE TOXICITY 82
8.3.3 HEPATOTOXICITY 82
8.3.4 OPHTHALMIC TOXICITY 82
8.3.5 CARDIOTOXICITY 82
8.3.6 NEPHROTOXICITY 82
8.3.7 NEUROTOXICITY 83
8.3.8 OTHERS 83
8.4 ASSAYS 83
8.4.1 CELL-BASED ELISA & WESTERN BLOTS 84
8.4.2 ENZYME TOXICITY ASSAYS 84
8.4.3 RECEPTOR-BINDING ASSAYS 84
8.4.4 BACTERIAL TOXICITY ASSAYS 84
8.4.5 TISSUE CULTURE ASSAYS 84
8.4.6 OTHER ASSAYS 84
8.5 EQUIPMENTS 85
8.6 SOFTWARE 86
9 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT AND TEST 87
9.1 OVERVIEW 88
9.2 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, & EXCRETION) TESTING 91
9.3 CYTOTOXICITY TESTING 92
9.4 GENOTOXICITY TESTING 93
9.5 DERMAL TOXICITY TESTING 94
9.6 OCULAR TOXICITY TESTING 95
9.7 ORGAN TOXICITY TESTING 96
9.8 SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING 97
9.9 PHOTOTOXICITY TESTING 97
9.10 OTHER TOXICITY ENDPOINTS AND TESTS 98
10 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 100
10.1 OVERVIEW 101
10.2 CELL CULTURE TECHNOLOGIES 104
10.3 HIGH-THROUGHPUT TECHNOLOGIES 105
10.4 MOLECULAR IMAGING 106
10.5 OMICS TECHNOLOGY 107
11 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY METHOD 108
11.1 OVERVIEW 109
11.2 CELLULAR ASSAYS 111
11.3 BIOCHEMICAL ASSAYS 112
11.4 EX-VIVO MODELS 113
11.5 IN SILICO MODELS 114
12 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY 116
12.1 OVERVIEW 117
12.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 120
12.2.1 CONSUMABLES 121
12.2.2 SERVICES 121
12.2.3 ASSAYS 121
12.2.4 EQUIPMENTS 121
12.2.5 SOFTWARE 121
12.3 DIAGNOSTICS 121
12.3.1 CONSUMABLES 123
12.3.2 SERVICES 123
12.3.3 ASSAYS 123
12.3.4 EQUIPMENTS 123
12.3.5 SOFTWARE 123
12.4 FOOD 123
12.4.1 CONSUMABLES 124
12.4.2 SERVICE 124
12.4.3 ASSAYS 124
12.4.4 EQUIPMENTS 125
12.4.5 SOFTWARE 125
12.5 CHEMICALS 125
12.5.1 CONSUMABLES 126
12.5.2 SERVICES 126
12.5.3 ASSAYS 126
12.5.4 EQUIPMENTS 126
12.5.5 SOFTWARE 126
12.6 COSMETICS AND HOUSEHOLD PRODUCTS 127
12.6.1 CONSUMABLES 128
12.6.2 SERVICES 128
12.6.3 ASSAYS 128
12.6.4 EQUIPMENTS 128
12.6.5 SOFTWARE 128
13 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY DISTRIBUTION CHANNEL 129
13.1 OVERVIEW 130
13.2 DIRECT TENDER 132
13.3 RETAIL SALES 133
13.4 OTHERS 134
14 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, BY REGION 136
14.1 NORTH AMERICA 137
14.1.1 U.S. 146
14.1.2 CANADA 151
14.1.3 MEXICO 156
15 NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET, COMPANY LANDSCAPE 161
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 161
16 SWOT ANALYSIS 162
17 COMPANY PROFILE 163
17.1 THERMO FISHER SCIENTIFIC INC. 163
17.1.1 COMPANY SNAPSHOT 163
17.1.2 REVENUE ANALYSIS 163
17.1.3 COMPANY SHARE ANALYSIS 164
17.1.4 PRODUCT PORTFOLIO 164
17.1.5 RECENT DEVELOPMENT 164
17.2 LABCORP DRUG DEVELOPMENT 165
17.2.1 COMPANY SNAPSHOT 165
17.2.2 REVENUE ANALYSIS 165
17.2.3 COMPANY SHARE ANALYSIS 166
17.2.4 PRODUCT PORTFOLIO 166
17.2.5 RECENT DEVELOPMENT 166
17.3 MERCK KGAA 167
17.3.1 COMPANY SNAPSHOT 167
17.3.2 REVENUE ANALYSIS 167
17.3.3 COMPANY SHARE ANALYSIS 168
17.3.4 PRODUCT PORTFOLIO 168
17.3.5 RECENT DEVELOPMENT 168
17.4 CHARLES RIVER LABORATORIES. 169
17.4.1 COMPANY SNAPSHOT 169
17.4.2 REVENUE ANALYSIS 169
17.4.3 COMPANY SHARE ANALYSIS 170
17.4.4 PRODUCT PORTFOLIO 170
17.4.5 RECENT DEVELOPMENT 170
17.5 LONZA 171
17.5.1 COMPANY SNAPSHOT 171
17.5.2 REVENUE ANALYSIS 171
17.5.3 COMPANY SHARE ANALYSIS 172
17.5.4 PRODUCT PORTFOLIO 172
17.5.5 RECENT DEVELOPMENT 172
17.6 AAT BIOQUEST, INC. 173
17.6.1 COMPANY SNAPSHOT 173
17.6.2 PRODUCT PORTFOLIO 173
17.6.3 RECENT DEVELOPMENTS 173
17.7 ARAGEN LIFE SCIENCES LTD. 174
17.7.1 COMPANY SNAPSHOT 174
17.7.2 REVENUE ANALYSIS 174
17.7.3 PRODUCT PORTFOLIO 175
17.7.4 RECENT DEVELOPMENT 175
17.8 BIOIVT 176
17.8.1 COMPANY SNAPSHOT 176
17.8.2 PRODUCT PORTFOLIO 176
17.8.3 RECENT DEVELOPMENT 176
17.9 BIO-RAD LABORATORIES, INC. 177
17.9.1 COMPANY SNAPSHOT 177
17.9.2 REVENUE ANALYSIS 177
17.9.3 PRODUCT PORTFOLIO 178
17.9.4 RECENT DEVELOPMENT 178
17.10 CATALENT, INC 179
17.10.1 COMPANY SNAPSHOT 179
17.10.2 REVENUE ANALYSIS 179
17.10.3 PRODUCT PORTFOLIO 180
17.10.4 RECENT DEVELOPMENT 180
17.11 CREATIVE BIOARRAY. 181
17.11.1 COMPANY SNAPSHOT 181
17.11.2 PRODUCT PORTFOLIO 181
17.11.3 RECENT DEVELOPMENTS 181
17.12 CREATIVE BIOLABS. 182
17.12.1 COMPANY SNAPSHOT 182
17.12.2 PRODUCT PORTFOLIO 182
17.12.3 RECENT DEVELOPMENTS 182
17.13 CYPROTEX LIMITED 183
17.13.1 COMPANY SNAPSHOT 183
17.13.2 PRODUCT PORTFOLIO 183
17.13.3 RECENT DEVELOPMENT 183
17.14 EUROFINS SCIENTIFIC 184
17.14.1 COMPANY SNAPSHOT 184
17.14.2 REVENUE ANALYSIS 184
17.14.3 PRODUCT PORTFOLIO 185
17.14.4 RECENT DEVELOPMENT 185
17.15 GENTRONIX 186
17.15.1 COMPANY SNAPSHOT 186
17.15.2 PRODUCT PORTFOLIO 186
17.15.3 RECENT DEVELOPMENT 186
17.16 IONTOX 187
17.16.1 COMPANY SNAPSHOT 187
17.16.2 PRODUCT PORTFOLIO 187
17.16.3 RECENT DEVELOPMENT 187
17.17 INSPHERO. 188
17.17.1 COMPANY SNAPSHOT 188
17.17.2 PRODUCT PORTFOLIO 188
17.17.3 RECENT DEVELOPMENT 188
17.18 INTERTEK GROUP PLC 189
17.18.1 COMPANY SNAPSHOT 189
17.18.2 REVENUE ANALYSIS 189
17.18.3 PRODUCT PORTFOLIO 190
17.18.4 RECENT DEVELOPMENT 190
17.19 MB RESEARCH LABORATORIES 191
17.19.1 COMPANY SNAPSHOT 191
17.19.2 PRODUCT PORTFOLIO 191
17.19.3 RECENT DEVELOPMENTS 191
17.20 PREFERRED CELL SYSTEMS 192
17.20.1 COMPANY SNAPSHOT 192
17.20.2 PRODUCT PORTFOLIO 192
17.20.3 RECENT DEVELOPMENTS 192
17.21 PROMEGA CORPORATION 193
17.21.1 COMPANY SNAPSHOT 193
17.21.2 PRODUCT PORTFOLIO 193
17.21.3 RECENT DEVELOPMENTS 194
17.22 QIAGEN 195
17.22.1 COMPANY SNAPSHOT 195
17.22.2 REVENUE ANALYSIS 195
17.22.3 PRODUCT PORTFOLIO 196
17.22.4 RECENT DEVELOPMENTS 196
17.23 SGS SOCIT GNRALE DE SURVEILLANCE SA 197
17.23.1 COMPANY SNAPSHOT 197
17.23.2 REVENUE ANALYSIS 197
17.23.3 PRODUCT PORTFOLIO 198
17.23.4 RECENT DEVELOPMENTS 198
17.24 SHANGHAI MEDICILON INC. 199
17.24.1 COMPANY SNAPSHOT 199
17.24.2 REVENUE ANALYSIS 199
17.24.3 PRODUCT PORTFOLIO 200
17.24.4 RECENT DEVELOPMENT 200
18 QUESTIONNAIRE 201
19 RELATED REPORTS 204

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.